Anti-inflammatory effects of a novel TNFR1-selective antagonistic TNF mutant on established murine collagen-induced arthritis

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 493-500

  Abe, Yasuhiro ^a   Nomura, Tetsuya ^a,b   Yoshioka, Yasuo ^a,b   Kamada, Haruhiko ^a,b   Tsunoda, Shin Ichi ^a   Tsutsumi, Yasuo ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; ANTIINFLAMMATORY AGENT; MUTANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CONFERENCE PAPER; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MUTANT PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954445805     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_51     Document Type: Conference Paper

References (35)

1. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 3:745-756
2. Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151-3158
3. Butler DM, Malfait AM, Mason LJ et al (1997) DBA/1 mice expressing the human TNFalpha transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition. J Immunol 159:2867-2876
4. Chowdhury PS, Pastan I (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17:568-572
5. Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133-3140
6. Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9: 1245-1250
7. Goh CR, Porter AG (1991) Structural and functional domains in human tumour necrosis factors. Protein Eng 4:385-389
8. Gomez-Reino JJ, Carmona L, Valverde VR et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 48:2122-2127
9. Grell M, Becke FM, Wajant H et al (1998) TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28:257-263
10. Grell M, Douni E, Wajant H et al (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802
11. Hoogenboom HR, Chames P (2000) Natural and designer binding sites made by phage display technology. Immunol Today 21:371-378
12. Kafrouni MI, Brown GR, Thiele DL (2003) The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J Leukoc Biol 74:564-571
13. Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 10:4025-4031
14. Kim EY, Priatel JJ, Teh SJ et al (2006) TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176:1026-1035
15. Kim EY, Teh HS (2001) TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 167:6812-6820
16. Kollias G, Kontoyiannis D (2002) Role of TNF/TNFR in autoimmunity: Specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13: 315-321
17. Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern Med J 37:705-712
18. Mohan N, Edwards ET, Cupps TR et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869
19. Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478-486
20. Mori L, Iselin S, De Libero G et al (1996) Attenuation of collagen-induced arthritis in 55- kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157:3178-3182
21. Mukai Y, Shibata H, Nakamura T et al (2009) Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385:1221-1229
22. Muto Y, Nouri-Aria KT, Meager A et al (1988) Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2:72-74
23. Olleros ML, Guler R, Corazza N et al (2002) Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette- Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 168: 3394-3401
24. Saunders BM, Tran S, Ruuls S et al (2005) Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174:4852-4859
25. Sblattero D, Bradbury A (2000) Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol 18:75-80
26. Shakoor N, MichalskaM, Harris CA et al (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579-580
27. Shibata H, Yoshioka Y, Abe Y et al (2009) The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 30:6638-6647
28. Shibata H, Yoshioka Y, Ohkawa A et al (2008a) The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 44:229-233
29. Shibata H, Yoshioka Y, Ohkawa A et al (2008b) Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 283:998-1007
30. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885-1888
31. Thorbecke GJ, Shah R, Leu CH et al (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89:7375-7379
32. van Oosten BW, Barkhof F, Truyen L et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531-1534.
33. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784-9788
34. Yamamoto Y, Tsutsumi Y, Yoshioka Y et al (2003) Site-specific PEGylation of a lysinedeficient TNF-alpha with full bioactivity. Nat Biotechnol 21:546-552
35. Yoshioka Y, Tsutsumi Y, Ikemizu S et al (2004) Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. Biochem Biophys Res Commun 315:808-814